Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Agilent Technologies Inc. announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.

Nanjing HumaDx Tech Co., Ltd. announced the completion of a Series A1 worth tens of millions of RMB, which was exclusively invested by Yuanbio Venture Capital, a well-known investment institution in the field of in vitro diagnostics.

QIAGEN announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for hereditary diseases.

Precision BioLogic said Thursday it secured US Food and Drug Administration 510(k) premarket clearance for its Cryocheck Chromogenic Factor IX test for managing hemophilia B.

Recently, an GDF-15 Chemiluminescence Immunoassay kit of Maccura Biotechnology Co., Ltd. obtained the medical certificate. This kit is the first certified Chemiluminescence Immunoassay kit for growth differentiation factor 15 in China.

General Electric completed the spinoff of its healthcare division on Wednesday morning as GE HealthCare began trading on the Nasdaq exchange under the ticker “GEHC” at $56 per share.

Foundation Medicine said Wednesday its FoundationOne Liquid CDx test has received approval from the US Food and Drug Administration as a companion diagnostic for Genentech's Rozlytrek (entrectinib).

Cytiva and Aurisco have cooperated to build Oligo FlexFactory production line project in Yangzhou. This production base has been invested hundreds of millions of yuan and can reach an annual production capacity of hundreds of kilograms of GMP-level small nucleic acid drugs once established.

Liquid biopsy oncology firm Burning Rock said on Tuesday that the U.S. Food and Drug Administration (FDA) has granted breakthrough device designation for its OverC Multi-Cancer Detection Blood Test (MCDBT).

Prostatype Genomics said on Monday that it has formed a commercialization alliance for its gene-based prostate cancer test with Swedish genetic testing provider Life Genomics.